glp-1 ms The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review glp 1 for ms patients
Description
This may be due to altered -cell function in diabetic patients, which impairs the efficacy of GLP-1(936)
How soon will I see results
This dual mechanism is what makes it more effective than single-agonist medications, but it also means the body needs adequate time to adjust to each dose increase
Introduction Metabolically driven pathologies, such as obesity, insulin resistance, and type 2 diabetes, but also immunologically mediated disorders, such as inflammatory bowel diseases (IBD), are considered chronic diseases
